相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review
Sharana Mahomed et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates
Ernest Asante-Appiah et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes
Nicolas Margot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Long-acting drugs and formulations for the treatment and prevention of HIV infection
Charles Flexner et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
Allosteric HIV Integrase Inhibitors Promote Formation of Inactive Branched Polymers via Homomeric Carboxy-Terminal Domain Interactions
Kushol Gupta et al.
STRUCTURE (2021)
Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial
Randolph P. Matthews et al.
NATURE MEDICINE (2021)
Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs
Steven J. Smith et al.
VIRUSES-BASEL (2021)
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study
Jared M Baeten et al.
Lancet HIV (2021)
A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants
Teodora Pene Dumitrescu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors
Lin Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
L. Corey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
HIV-1 Entry and Membrane Fusion Inhibitors
Tianshu Xiao et al.
VIRUSES-BASEL (2021)
HIV Protease: Historical Perspective and Current Research
Irene T. Weber et al.
VIRUSES-BASEL (2021)
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Chloe Orkin et al.
Lancet HIV (2021)
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial
Jean-Michel Molina et al.
LANCET HIV (2021)
A Small Molecule, ACAi-028, with Anti-HIV-1 Activity Targets a Novel Hydrophobic Pocket on HIV-1 Capsid
Travis Chia et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Raphael J. Landovitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir
Nagsen Gautam et al.
NATURE COMMUNICATIONS (2021)
Optimized binding of substituted quinoline ALLINIs within the HIV-1 integrase oligomer
Jian Sun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses
Yue Ma et al.
CHEMICAL SOCIETY REVIEWS (2021)
Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3
Martin Markowitz et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis
Nithya Srinivas et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
Jean van Wyk et al.
CLINICAL INFECTIOUS DISEASES (2020)
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Susan Swindells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Curing HIV: Seeking to Target and Clear Persistent Infection
David M. Margolis et al.
CELL (2020)
The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes
Jennifer Gorwood et al.
CLINICAL INFECTIOUS DISEASES (2020)
Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance
Francesc Xavier Ruiz et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2020)
Novel Approaches Towards a Functional Cure of HIV/AIDS
Lucia Bailon Alvarez et al.
DRUGS (2020)
Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials
Xingbao Tao et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
Dirk Schuermann et al.
LANCET HIV (2020)
Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients
Anne-Genevieve Marcelin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Michael Kozal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tenofovir resistance in early and long-term treated patients on first-line antiretroviral therapy in eight low-income and middle-income countries
Seth C. Inzaule et al.
AIDS (2020)
Clinical targeting of HIV capsid protein with a long-acting small molecule
John O. Link et al.
NATURE (2020)
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety
Kimberly K. Scarsi et al.
DRUGS (2020)
Long-Acting Injectable Cabotegravir plus Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
Giuliano Rizzardini et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2020 Recommendations of the International Antiviral Society-USA Panel
Michael S. Saag et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction
Sizhu Duan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Structural Biology of HIV Integrase Strand Transfer Inhibitors
Ilona K. Jozwik et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
HIV-1 Maturation: Lessons Learned from Inhibitors
Alex B. Kleinpeter et al.
VIRUSES-BASEL (2020)
Recent discoveries in HIV-1 reverse transcriptase inhibitors
Shuang-Xi Gu et al.
CURRENT OPINION IN PHARMACOLOGY (2020)
Structural and mechanistic bases for a potent HIV-1 capsid inhibitor
Stephanie M. Bester et al.
SCIENCE (2020)
Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings
Craig J. Hoesley et al.
CLINICAL INFECTIOUS DISEASES (2019)
Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Albert Y. Liu et al.
CLINICAL INFECTIOUS DISEASES (2019)
Review: HIV-1 phylogeny during suppressive antiretroviral therapy
Michael J. Bale et al.
CURRENT OPINION IN HIV AND AIDS (2019)
Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants
Shin-ichiro Hattori et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
Willem D. F. Venter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Hans-Juergen Stellbrink et al.
LANCET HIV (2019)
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
David A. Wohl et al.
LANCET HIV (2019)
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1:100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies
Michael Aboud et al.
LANCET HIV (2019)
Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus
Enzo Tramontano et al.
ANTIVIRAL RESEARCH (2019)
A HTRF based competitive binding assay for screening specific inhibitors of HIV-1 capsid assembly targeting the C-Terminal domain of capsid
Da-Wei Zhang et al.
ANTIVIRAL RESEARCH (2019)
Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment
Yali Wang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Pedro Cahn et al.
LANCET (2019)
Update on Adverse Effects of HIV Integrase Inhibitors
Agnieszka Kolakowska et al.
CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES (2019)
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir
Nicholas A. Meanwell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Novel Latency Reversal Agents for HIV-1 Cure
Adam M. Spivak et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention
Stephanie E. Barrett et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
NCp7: targeting a multitask protein for next-generation anti-HIV drug development part 2. Noncovalent inhibitors and nucleic acid binders
Nunzio Iraci et al.
DRUG DISCOVERY TODAY (2018)
Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717
J. A. Perez-Molina et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
4-Ethynyl-2-fluoro-2-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor
Martin Markowitz et al.
CURRENT OPINION IN HIV AND AIDS (2018)
The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase
Yuki Takamatsu et al.
CELL CHEMICAL BIOLOGY (2018)
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Paul E. Sax et al.
LANCET (2017)
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Joel Gallant et al.
LANCET (2017)
Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women
A. Nel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA)
Zhe Li Salie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial
J. D. Baxter et al.
HIV MEDICINE (2015)
Efavirenz and the CNS: what we already know and questions that need to be answered
Nadezda Apostolova et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms
Eleftherios Michailidis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Host Cofactors and Pharmacologic Ligands Share an Essential Interface in HIV-1 Capsid That Is Lost upon Disassembly
Amanda J. Price et al.
PLOS PATHOGENS (2014)
Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments
Luis Menendez-Arias
ANTIVIRAL RESEARCH (2013)
Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope
Craig S. Pace et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV
Erik De Clercq
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131
Tomas Cihlar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
分享论文
